Jennifer Woyach: Ibrutinib Outperforms Chemoimmunotherapy in CLL
Dr. Woyach shares findings from her plenary abstract, in which ibrutinib improved survival outcomes in older patients with chronic lymphocytic leukemia, compared with a standard-of-care regimen of rituximab and bendamustine.
Видео Jennifer Woyach: Ibrutinib Outperforms Chemoimmunotherapy in CLL канала American Society of Hematology
Видео Jennifer Woyach: Ibrutinib Outperforms Chemoimmunotherapy in CLL канала American Society of Hematology
Показать
Комментарии отсутствуют
Информация о видео
3 декабря 2018 г. 8:39:09
00:04:39
Другие видео канала
Relapsed and Refractory Disease and Emerging Therapies
Blood Advances Highlights - Quality and Scope
64th ASH Annual Meeting & Exposition | 2022 | New Orleans, LA
ASH News TV 2022: ASH Guideline Implementation Champions
2017 Promoting Minorities in Hematology Presentations and Reception
Blood Review Series – Adolescent and Young Adult Malignant Hematology
Sickle Cell Disease Coalition (SCDC)
Inside ASH Central & ASH Store
The ASH Agenda for Hematology Research: Immunotherapy
The Balancing Act of Caring for Older Patients with Hemophilia
ASH Scholar Awards - Investing in Innovators for Over 30 Years
What to Expect at 2017 ASH Annual Meeting
Raajit Rampal, MD, PhD & Naveen Pemmaraju, MD: MANIFEST-2 and Transform-1 Trials
2016 Highlights of ASH® in Latin America
ASH News TV 2022: Press Briefings
Meet the Editor: Cynthia Dunbar, MD
ASH News TV 2022: ASH Education Program Session on Pediatric Leukemia
ASH News TV 2022: Medical Educators Symposium
Harvey Lodish Receives 2021 Wallace H. Coulter Award for Lifetime Achievement in Hematology
2017 Highlights of ASH® in North America
Blood Advances